melanoma

Castle Biosciences commercializing tests for orphan cancers, raising $11.8M

Texas cancer diagnostics company Castle Biosciences plans to expand the clinical availability of its tests that assess “rare and underserved cancers,” particularly one for cutaneous melanoma. It has wrapped up an $11.8 million round to do so, the company said. The round was led by new investor HealthQuest Capital; existing investors Mountain Group Capital and Affiliates, Longfellow […]

presented by